SPIRIVA RESPIMAT Inhalation Spray is now available by prescription through retail pharmacies across the United States for the long-term, once-daily maintenance treatment of bronchospasm associated ...

WEDNESDAY, Sept. 6, 2017 -- The inhaler medication Spiriva (tiotropium bromide) may help slow the progression of COPD if given in the early stages of the disease, a new study suggests. Researchers ...

-- Patients to Benefit From Easy-to-Use Inhaler With Enhanced Drug Delivery Boehringer Ingelheim and Pfizer today announced successful completion of the approval process for authorisation to market ...

Long-term, Head-to-Head Study Showed SPIRIVA HandiHaler (tiotropium bromide inhalation powder) Significantly Prolonged Time to First Moderate or Severe COPD Exacerbation versus Salmeterol HFA-MDI The ...

Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...

RIDGEFIELD, Conn., March 29, 2018 /PRNewswire/ -- Boehringer Ingelheim announced today that data from the DYNAGITO trial, a 52-week study involving more than 7,800 people across a broad range of COPD ...

Federal health regulators said Thursday that recent data do not show a connection between a popular inhaler and previously reported risks of stroke, heart attack and death. The Spiriva HandiHaler is ...

Lannett has entered into an exclusive U.S. commercialization agreement for generic Spiriva Handihaler (Tiotropium Bromide inhalation powder) with Respirent Pharmaceuticals. The 10-year term of the ...

Major League Baseball’s annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema. The television spots were created by ...

DUBLIN--(BUSINESS WIRE)--The "Spiriva" report has been added to ResearchAndMarkets.com's offering. Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for ...

Scientists of a U.S. government-funded asthma study had to spend nearly $1 million of taxpayers' money after British drugmaker GlaxoSmithKline PLC declined to donate its asthma drug and look-alike ...

U.S. study finds 'excess number of deaths' after major study A mist inhaler used to improve breathing in people with lung diseases including chronic bronchitis and emphysema could increase the risk of ...